Article Listing - BioMarin's 2nd-qtr 2007 loss widens to $3.9M

SOMBRE FUTURE FOR GENERALIST DRUG-MAKERS IN FRANCE?

9 March 1992

In contrast to specialist drug firms such as Innothera, which successfully exploit a niche in the drug market, generalist pharmaceutical...

FURTHER WELLCOME SHARE SELL-OFF

9 March 1992

Six years after the first share floatation in UK drugmaker Wellcome, the Wellcome Trust has revealed that a further tranche...

TURNOVER UP 39% AT LUNDBECK UK

9 March 1992

In the UK, pharmaceutical concern Lundbeck says it is set for a healthy future following its latest annual results. For...

INNOTHERA SEEKING DEVELOPMENT CASH

9 March 1992

The French drug manufacturer, Innothera, which specializes in products for women's diseases, says it is ready to open its capital...

WARNING LETTER TO MILES ON NIMOTOP

9 March 1992

Promotion of the neurone-specific calcium channel blocker Nimotop (nimodipine) in the USA by Miles Laboratories for the unapproved indication of...

BULLETIN REVIEWS NEW TOPICAL PRODUCTS

9 March 1992

Leo Laboratories' Dovonex (calcipotriol) represents an interesting and useful addition to the menu of treatments available for chronic plaque psoriasis,...

MEDEVA'S NEW CORACTEN FORM

9 March 1992

Medeva plc and its subsidiary Evans Medical have launched in the UK a new product in the Coracten (nifedipine) range....

UK DTP VACCINATION SCHEDULE

9 March 1992

New findings released by a team of UK clinicians, under the direction of Robert Booy of the Radcliffe Hospital, Oxford,...

US APPROVAL FOR CARDENE SR

9 March 1992

Syntex Corp has received approval from the US Food and Drug Administration to market its Cardene SR, a slow-release formulation...

BIOCHEM PHARMA'S JOHN GILLARD

9 March 1992

John Gillard has been appointed as director of therapeutic research at BioChem Pharma Inc of Canada. 1614869 COST CONTAINMENT MEASURES...

Showing 94731-94740 of 95329 articles